Novel Insights Into Congenital and Acquired Coagulopathies – ICHCC
Iranian Comprehensive Hemophilia Care Center (ICHCC) shared a post on LinkedIn about a recent article by Rabab Al Dawood et al, published in Pathology, adding:
“Laboratory diagnosis of congenital and acquired coagulopathies, including challenging-to-diagnose rare bleeding disorders.
Coagulation factors, anticoagulant proteins, and fibrinolytic proteins are important for hemostasis and may be altered by inherited and acquired conditions.
Common causes of coagulopathies include vitamin K (VK) deficiency (VKD), liver disease, lupus anticoagulants, consumption or disseminated intravascular coagulation, and much less commonly, an inherited or an acquired autoimmune coagulopathy.
VKD typically accounts for more than 30 percent of all coagulopathy referrals, and VKD is particularly common among infants but can occur at any age and in combination with other coagulopathies.
Tests for fibrinogen help assess both congenital and acquired coagulopathies, with low levels predictive of poor outcomes from diverse conditions including trauma and postpartum hemorrhage.
Inherited factor deficiencies are rarer, and some affect multiple coagulation factors (F), such as combined FV and FVIII deficiency, familial deficiencies of VK-dependent clotting factors, and congenital disorders of glycosylation.
Additionally, there are some rare but important disorders that uniquely impair the procoagulant/anticoagulant balance, including F5 mutations that markedly increase tissue factor pathway inhibitor in plasma, causing prolonged prothrombin and activated partial thromboplastin times, without factor deficiencies.
THBD mutations that increase functional, soluble thrombomodulin in plasma can also cause bleeding.
Other THBD mutations cause thrombomodulin deficiency and a consumptive coagulopathy.
Bleeding disorders that result from pathogenic changes to fibrinolysis include autosomal recessive, loss-of-function mutations in SERPINE1 and SERPINF2 and an autosomal dominant gain-of-function mutation affecting PLAU, in the case of Quebec platelet disorder, which causes platelet-dependent increased fibrinolysis.
Laboratories need to consider strategies for diagnosing these different conditions.”
Title: Laboratory diagnosis of congenital and acquired coagulopathies, including challenging-to-diagnose rare bleeding disorders
Authors: Rabab Al Dawood, Catherine P.M. Hayward

Stay updated on all scientific advances with Hemostasis Today.
-
May 26, 2026, 14:24Fernanda Orsi: The Growing Impact of Hematology Research in Latin America
-
May 26, 2026, 14:23Rense Buijvoets: What If Clots Could Be Treated Exactly Where They Form?
-
May 26, 2026, 14:14Fredrick Chalinga: The Reality of Massive Transfusion in Emergency Medicine
-
May 26, 2026, 14:09Tareq Abadl: Slide Method vs Tube Method in Blood Grouping
-
May 26, 2026, 14:07Fernanda Flygare: HI-PEITHO Trial Highlights Benefits of EKOS-Assisted Catheter-Directed Thrombolysis in PE
-
May 26, 2026, 14:05Arvind Kumar: The Science Behind Clot Retraction in Hemostasis
-
May 26, 2026, 14:01Maria Fredin Grupper: WHA79 Adopts Landmark WHO Resolution on Stroke
-
May 26, 2026, 13:54Awareness Enables Diagnosis, Diagnosis Enables Care, and Care Changes Lives – EHC
-
May 26, 2026, 13:47Masoabi Sefojane: Reflections on Bleeding Disorder Care in LMICs From the WFH Africa Regional Workshop